Direct-to-consumer genetic testing: failure is not an option
- PMID: 19536117
- PMCID: PMC3086846
- DOI: 10.1038/clpt.2009.63
Direct-to-consumer genetic testing: failure is not an option
Abstract
Direct-to-consumer genetic testing is an unavoidable consequence of our ability to cheaply and accurately measure the genome. Some are troubled by the loss of control over how and when this information is disclosed to individuals, but it is difficult to imagine any way to prevent the wide availability of these data. Therefore, the key challenge is to set up social, educational, and technical means to support individuals who have access to their genome.
Conflict of interest statement
The author is a paid adviser to 23andMe, a DTC genomic testing and interpretation company.
Comment in
-
Direct-to-consumer genetic testing: the need to get retail genomics right.Clin Pharmacol Ther. 2009 Jul;86(1):17-20. doi: 10.1038/clpt.2009.56. Clin Pharmacol Ther. 2009. PMID: 19536118 Review. No abstract available.
References
-
- Pollack A. Dawn of low-price mapping could broaden DNA uses. New York Times. 2008 Oct 6;
-
- Pollack A. Gene testing questioned by regulators. New York Times. 2008 Jun 26;
-
- Pollack A. Congress near deal on genetic test bias bill. New York Times. 2008 Apr 23;
-
- Malin B, Sweeney L. How (not) to protect genomic data privacy in a distributed network: using trail re-identification to evaluate and design anonymity protection systems. J. Biomed. Inform. 2004;37:179–192. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
